M. F. Beketova

M. F. Beketova

Auto-generated profile, based on publicly available information

M. F. Beketova

V.A. Nasonova Research Institute of Rheumatology

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
TBTatiana Beketova
Tatiana Beketova
NLN. O. Levina
N. O. Levina
DLD. O. Ladygina
D. O. Ladygina
VBV. V. Babak
V. V. Babak
MBM. F. Beketova
M. F. Beketova
TKT. N. Krasnova
T. N. Krasnova
Coronavirus disease 2019 (COVID-19) can manifest with a wide range of extrapulmonary symptoms and have longterm consequences (so-called post-covid syndrome (PCS) or “long COVID-19”). Manifestations of PCS show a wide clinical spectrum and include cardiac, pulmonary, neurological, gastrointestinal, dermatological, mental symptoms, vascular thrombosis and avascular necrosis (AVN) of the bones.We present our own observations of the development of bone’s AVN in 3 patients who underwent COVID-19 with bilateral lung disease, in whom after 4–6 months the first signs of AVN were noted and characterized by a progressive multifocal lesion, which was accompanied by an increase of C-reactive protein concentration.The pathogenetic mechanisms of AVN development in the framework of PCS are discussed. The importance of conservative and surgical methods in the treatment of the disease are considered. Since the development of AVN of various localizations with a long latent period is possible after COVID-19, long-term monitoring of patients is required. Further study of the problem of PCS in general and AVN in particular is required.

28 April 2023 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
TBTatiana Beketova
Tatiana Beketova
NLN. О. Levina
N. О. Levina
MDM. V. Dubinskaia
M. V. Dubinskaia
YUYu. A. Uskova
Yu. A. Uskova
IRI. V. Rozanova
I. V. Rozanova
TKT. N. Krasnova
T. N. Krasnova
The problem of prevention of coronavirus disease 2019 (COVID-19) in patients with immune-mediated inflammatory rheumatic diseases (IMRD) remains highly relevant. The presence of IRD is associated with a high risk of disease and severe course of COVID-19 during immunosuppressive treatment, primarily anti-B cell therapy with rituximab (RTX), and a low level of post-vaccination response in such patients. A new strategy for the prevention and treatment of COVID-19 are virus-neutralizing monoclonal antibodies to coronavirus; currently, combined long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld) are registered for prevention in the world and the Russian Federation. . Tixagevimab and cilgavimab (TC) show neutralizing activity against SARS-CoV-2, including the Omicron strain, primarily its variants BA.4, BA.5, BA.2.75 ("Centaur").Objective – to evaluate the efficacy and safety of TC for pre-exposure prophylaxis of COVID-19 in rheumatic patients receiving RTX, based on a prospective observational study.Materials and methods. The main group included 86 patients with various IMRD receiving RTX: 50 of them had ANCA-associated systemic vasculitis (AAV), 15 – rheumatoid arthritis, 9 – Sjogren’s syndrome (SS), 4 – IgG4-related disease, 3 – systemic lupus erythematosus (SLE), 3 – dermatomyositis (DM), 2 – systemic scleroderma (SSD). Median age was 59 (19–82) years; male : female ratio – 1:1,8. From March 26 to August 30 2022, patients received a single intramuscular injection of TC in a total dose of 300 mg, mainly after RTX (in 52% of cases, in 28% on the next day after RTX). The control group included 42 patients with AAV (median age – 45 (35–71) years; male : female ratio – 1:1), also treated with RTX, who did not receive pre-exposure prophylaxis of TC. The duration of observation was 7 months, until November 1 2022. At this time, 98% of confirmed cases of coronavirus in the Russian Federation were Omicron. A telephone and/or online survey of patient has been conducted to detect cases of COVID-19 and adverse reactions.Results. In the TC group, confirmed coronavirus infection have been detected in 17 (20%) patients (AAV – 10, SS – 3, SSD – 2, SLE – 1, DM – 1), with fever in 7 (8%), only in one case hospitalization was required (lung damage was not detected in computed tomography), in two cases, according to CT mild lung damage (CT 1–2), there were no deaths. Good TC’s tolerability was noted, signs not associated with COVID-19 or progression of IMRD after administration of TC were observed in 8 (9%) patients (GPA – 3 MPA – 1, RA – 2, SLE – 1, IgG4-related disease – 1), adverse reactions definitely associated with the use of TC were not found. The most serious event not associated with coronavirus infection was the progression of polyneuropathy in a patient with RA. In the control group, 3 (7%) patients were diagnosed with COVID-19, one with severe lung injury (CT 3, pulmonary embolism) and death.Conclusions. The data of clinical studies and our own clinical experience evidence the effectiveness of the use of a combination of long-acting monoclonal antibodies TC (Evusheld), registered for indications for pre-exposure prophylaxis and treatment of COVID-19. Patients with IMRD treated with RTX have a favorable safety profile of TC. The introduction of virus-neutralizing monoclonal antibodies, a new drug class for the prevention and treatment of infectious diseases, opens significant prospects for improving the prognosis of patients with IRD.

19 February 2026 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
MBM. F. Beketova
M. F. Beketova
SSS. O. Salugina
S. O. Salugina
EFE. S. Fedorov
E. S. Fedorov
ATA. V. Torgashina
A. V. Torgashina
EZEKATERINA ZAKHAROVA
EKATERINA ZAKHAROVA
ALAleksandr M Lila
Aleksandr M Lila
In the last decade, an interest has increased in autoinflammatory diseases (AIDs) associated with a mutation in a specific gene, while the pathogenetic significance of the identified genetic variants continues to be clarified. Objective: to study the frequency and spectrum of genetic variants identified by molecular genetic testing (MGT) and the clinical features in patients with suspected monogenic AIDs (mAIDs). Material and methods. MGT of target genes was performed in 115 patients with suspected mAIDs (median age 10 [5; 14] years; male-to-female ratio 1:1.1) using massively parallel sequencing (in 89% of cases, a 65-gene panel was used). Results and discussion. The patients were divided into two groups. Group 1 included 44 (38%) patients with identified genetic variants, and Group 2 included 71 patients with genetically negative MGT results. Thirty-six monogenic variants were identified (11 in the MEFV gene, 5 in NOD2, 4 in NLRP3, 3 in TNFRSF1A, 2 each in MVK, RAG1, NLRP1, ADA2, and 1 each in IFIH1, NLRP12, UNC13D, RIPK1, IL36RN), as well as 8 digenic/oligogenic combinations (2 in MEFV/TNFRSF1A; 1 each in MEFV/MVK/TNFAIP3, MEFV/NOD2/PSTPIP1, NOD2/MEFV, IL36RN/STX11, MEFV/NLRP12, SH2D1A/TNFAIP3). In both groups, the most common were: fever (in 89% and 88% of cases), skin involvement (59% and 47%), arthralgia (61% and 45%), arthritis (36% and 25%), gastrointestinal symptoms (34% and 37%), and lymphadenopathy (28% and 35%), hyperproduction of autoantibodies was detected in 15% and 27% of cases, respectively. Differences between the groups for these parameters were not statistically significant. Chest pain was observed significantly more often in Group 1 than in Group 2 (14% vs 1%, respectively; p=0.008). Conclusion. MGT identified mutations in 38% of patients with suspected mAIDs. Genetic variants from the group of major monogenic AIDs (FMF, TRAPS, CAPS, HIDS/MKD) were most common. When clinical and laboratory data were compared between the groups with positive and negative MGT results, no substantial differences were found. Patients with negative MGT results who meet AIDs criteria require extended evaluation, including whole-exome/whole-genome sequencing.

31 August 2023 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
TBTatiana Beketova
Tatiana Beketova
MBM. F. Beketova
M. F. Beketova
ENE. L. Nasonov
E. L. Nasonov
The article is dedicated to a new actual problem in rheumatology: vasculitis and vasculitis-like manifestations in monogenic autoinflammatory syndromes in adult. The features of the clinical course of the rarely diagnosed VEXAS syndrome, as well as the SAVI and COPA syndromes, which sometimes occur in adults, are considered. Promising directions of future treatment are discussed.

14 May 2022 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
MBM. F. Beketova
M. F. Beketova
VBV. V. Babak
V. V. Babak
MSM. D. Suprun
M. D. Suprun
TBTatiana Beketova
Tatiana Beketova
OGO. A. Georginova
O. A. Georginova
Actual problems of rheumatology include the possibility of developing a wide range of long-term consequences of COVID-19, so-called post-COVID syndrome (PCS). The results of our own research are presented, during which among 45 patients over 18 years with rheumatic diseases (RD) PCS was detected in 20% cases: 6 of them had ANCAassociated vasculitis (AAV) and one each for rheumatoid arthritis, juvenile arthritis and osteoarthritis. In AAV cases PCS was more severe and varied than in other RD: lung lesions according to computed tomography (up to the damage 75% of the lung parenchyma), skin an d nervous (Guillain–Barré syndrome) lesions, myalgias, arthralgias were present. In most patients PCS ended in recovery, sudden death occurred only in the patient with AAV. The frequency of RD’s relapses in patients with PCS was 9%. Relapses were not noted in AAV, against the background of anti-B cell therapy with rituximab. Our own results and literature data indicate that patients with RD after COVID-19 need careful continuous monitoring to detect long-term complications of coronavirus infection and early diagnosis of relapses of the underlying disease.

22 December 2025 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
SSS. O. Salugina
S. O. Salugina
EFE. S. Fedorov
E. S. Fedorov
ATA. V. Torgashina
A. V. Torgashina
MKM. I. Kaleda
M. I. Kaleda
MBM. F. Beketova
M. F. Beketova
ASA. Yu. Sukhanina
A. Yu. Sukhanina
Autoinflammatory diseases (AIDs) represent a heterogeneous group of conditions pathogenetically associated with dysregulation of innate immunity and clinically characterized by recurrent episodes of sterile inflammation in affected organs in the absence of infection, allergy, and high titers of circulating autoantibodies or autoreactive T cells. The overwhelming majority of monogenic AIDs (mAIDs) are accompanied by skin rashes, the type of which is determined by the specific disease and, to some extent, by differing pathogenetic mechanisms. The first part of the article presents the cutaneous characteristics of the most common mAIDs: Familial Mediterranean fever (FMF), cryopyrinassociated periodic syndromes (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), periodic syndrome with hyperimmunoglobulinemia D / mevalonate kinase deficiency (HIDS/MKD). Skin involvement in these diseases reflects systemic inflammation associated with hyperproduction of the key pro-inflammatory cytokine interleukin (IL)-1β. In other AIDs, symptoms mainly depend on increased levels of cytokines such as IL-18, IL-36, etc. (NLRC4-associated autoinflammatory disease; deficiency of the IL-36 receptor antagonist – DITRA), as well as activation of interferon signaling pathways (interferonopathies). Different pathogenetic mechanisms determine the diversity of clinical phenotypes, including cutaneous manifestations. Knowledge of these features helps establishing a correct diagnosis, obtaining genetic confirmation (without which accurate identification of these rare conditions is impossible today) and selecting appropriate therapy. Pathological examination plays a special auxiliary role and should be used in diagnostically challenging situations.